Medical Device News Magazine

Hackensack Meridian Neuroscience Institute at JFK University Medical Center Receives $2.2 Million Research Grant to Study A Novel Traumatic Brain Injury Treatment

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Hackensack Meridian Neuroscience Institute at JFK University Medical Center

Hackensack Meridian Neuroscience Institute at JFK University Medical Center announced today that it has been awarded a major research grant from the National Institute of Neurological Disorders and Stroke, part of the U.S. National Institutes of Health, to study a novel approach on whether the blocking of formation of Neutrophil extracellular traps (NET) provides better outcomes after a Traumatic Brain Injury (TBI). The five-year award of $2,213,750 is part of the highly competitive NIH extramural grant application process that recognizes innovative scientific projects. NIH-funded research has led to scientific breakthroughs and new treatments that help people live longer, healthier lives.

Neutrophil Extracellular Traps And Associated Pathogenesis In TBI: A Novel Peptide Therapeutic Strategy

The NIH grant will fund a project entitled “Neutrophil Extracellular Traps And Associated Pathogenesis In TBI: A Novel Peptide Therapeutic Strategy” proposed by Mohammed Abdul Muneer, MSc, PhD, Research Scientist & Principal Investigator, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Associate Professor of Neurology at the Hackensack Meridian School of Medicine.

The work hypothesizes that inhibition of peptidyl arginine deiminase type 4 (PAD4), an enzyme required for NET formation, using PAD4 antagonistic peptide (PAP), will attenuate the formation of NET, NET-induced thrombosis, and will promote neovascularization and functional recovery after TBI.

Gregory J. Przybylski, M.D.

“We are honored to receive this prestigious NIH grant,” said Gregory J. Przybylski, M.D., MBA, chairman, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Professor of Neurosurgery at the Hackensack Meridian School of Medicine. “I congratulate Dr. Muneer and his team for this incredible achievement. This is yet another research grant that he has received from the NIH. It is a testament to his hard work, dedication, and leadership in the neuroscience field.”

The Muneer lab at the Hackensack Meridian Neuroscience Institute at JFK University Medical Center seeks to demonstrate a unique therapeutic strategy for TBI focusing on the activation of leukocytes, especially neutrophils that cause the release of nuclear and granular contents to form an extensive web-like structure of DNA called neutrophil extracellular traps (NET). In TBI, the mechanism of injury-induced formation of NET and its mechanistic regulatory role in thrombosis have remained elusive. Moreover, it is unclear whether blocking NET formation provides better outcomes after TBI. Therefore, Dr. Muneer’s novel research efforts to suppress the formation of NET will provide critical information potentially supporting a valuable new therapeutic strategy to enhance functional recovery following TBI.

“My research team and I will study an approach to suppressing the formation of NET, which may be a valuable therapeutic strategy, and analyze the efficacy of the therapy in the functional recovery level after TBI,” said Dr. Muneer.

“The Neuroscience Institute at JFK University Medical Center has been in existence for over 30 years,” said Gay Holstein, PhD, translation research, Neuroscience Institute at JFK University Medical Center. “We are honored to receive this research grant and look forward to the findings.”

Ihor Sawczuk, M.D.

“TBI is such an omnipresent problem, it’s critical to have our talented researchers findings new ways to improve and lengthen lives for this significant patient population,” said Ihor Sawczuk, M.D., FACS, president of Academics, Research, and Innovation at Hackensack Meridian Health, founding chair of the Hackensack Meridian Health Research Institute, and associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”